New antibody drug aims to outsmart Treatment-Resistant myeloma
NCT ID NCT07695740
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This phase 2 trial tests an investigational drug called YKST02 in adults with multiple myeloma that has relapsed or stopped responding to prior treatments. YKST02 is a bispecific antibody designed to bind both myeloma cells and immune T cells, potentially helping the immune system destroy the cancer. The study will measure how well the drug shrinks tumors, monitor side effects, and examine how the body processes the medication. About 64 participants will receive YKST02 by intravenous infusion and undergo regular assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YKST02 (a bispecific antibody that targets myeloma cells and activates immune T cells)
- What this could lead to
- If successful, YKST02 could offer a new treatment option for people with multiple myeloma whose cancer has returned or stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with only 64 participants, so results may not apply to all patients. Side effects, including immune reactions, are possible and not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chao-yang Hospital, Capital Medical University
Beijing, Beijing Municipality, 100024, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists test CAR-T cells made inside the body to fight Hard-to-Treat myeloma
- New hope for Tough-to-Treat blood cancer: phase 3 trial launched
- New Three-Drug cocktail aims to tackle Hard-to-Treat multiple myeloma
- Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma
- Double-Barreled CAR-T attack on Hard-to-Treat myeloma
- New antibody drug tested for tough blood cancers – but trial stopped early